Andrew Spaventa Sells 800 Shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) Stock

Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa sold 800 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $19.89, for a total value of $15,912.00. Following the transaction, the chief executive officer now directly owns 1,432 shares of the company’s stock, valued at approximately $28,482.48. This trade represents a 35.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Spaventa also recently made the following trade(s):

• On Monday, December 16th, Andrew Spaventa sold 180 shares of Singular Genomics Systems stock. The stock was sold at an average price of $20.16, for a total value of $3,628.80.

Singular Genomics Systems Trading Up 0.1 %

NASDAQ:OMIC opened at $19.96 on Friday. Singular Genomics Systems, Inc. has a twelve month low of $5.34 and a twelve month high of $23.41. The company has a quick ratio of 6.67, a current ratio of 7.37 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average price of $19.79 and a two-hundred day moving average price of $15.93.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($6.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The company had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.74 million.

Institutional Investors Weigh In On Singular Genomics Systems

An institutional investor recently raised its position in Singular Genomics Systems stock. Geode Capital Management LLC lifted its stake in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,962 shares of the company’s stock after purchasing an additional 1,193 shares during the period. Geode Capital Management LLC owned 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent quarter. 65.80% of the stock is currently owned by institutional investors.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.